Literature DB >> 10404315

5-Fluorocytosine antagonizes the action of sterol biosynthesis inhibitors in Candida glabrata.

H Siau1, D Kerridge.   

Abstract

The concentration-dependent antagonistic interaction between 5-fluorocytosine and a sterol biosynthesis inhibitor (SBI) was studied using intact cells and cell-free extracts of Candida glabrata. 5-Fluorocytosine promoted incorporation of radioactivity into 4-desmethylsterols (P < 0.01), and enhanced the relative and absolute increases of ergosterol (P < 0.05) in C. glabrata incubated aerobically with an SBI (miconazole or amorolfine). Further aerobic incubation of C. glabrata with combinations of a nucleic acid or protein synthesis inhibitor (rifampicin or chlortetracycline) and an SBI (miconazole) promoted a similar increase in ergosterol biosynthesis. In contrast, 5-fluorocytosine reduced the incorporation of radioactivity into 4,4-dimethylsterols (P < 0.01), but had no obvious effect on the absolute ergosterol level in C. glabrata incubated statically with miconazole. In cell-free extracts of cultures previously incubated with 5-fluorocytosine, ergosterol synthesis was less sensitive to the action of miconazole. Antagonism between 5-fluorocytosine and the SBI is thus mediated by a reversal of inhibition of intracellular ergosterol synthesis. The possible mechanisms underlying antagonism between 5-fluorocytosine and SBIs that inhibit different sites of the sterol biosynthesis pathway, as well as its clinical relevance to combination therapy, are discussed.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10404315     DOI: 10.1093/jac/43.6.767

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  7 in total

Review 1.  Combination antifungal therapy.

Authors:  Melissa D Johnson; Conan MacDougall; Luis Ostrosky-Zeichner; John R Perfect; John H Rex
Journal:  Antimicrob Agents Chemother       Date:  2004-03       Impact factor: 5.191

2.  Mutational analysis of flucytosine resistance in Candida glabrata.

Authors:  Thomas D Edlind; Santosh K Katiyar
Journal:  Antimicrob Agents Chemother       Date:  2010-09-07       Impact factor: 5.191

Review 3.  Antifungal combination therapy: clinical potential.

Authors:  John W Baddley; Peter G Pappas
Journal:  Drugs       Date:  2005       Impact factor: 9.546

4.  Raman Study of Pathogenic Candida auris: Imaging Metabolic Machineries in Reaction to Antifungal Drugs.

Authors:  Giuseppe Pezzotti; Miyuki Kobara; Tamaki Nakaya; Hayata Imamura; Tenma Asai; Nao Miyamoto; Tetsuya Adachi; Toshiro Yamamoto; Narisato Kanamura; Eriko Ohgitani; Elia Marin; Wenliang Zhu; Ichiro Nishimura; Osam Mazda; Tetsuo Nakata; Koichi Makimura
Journal:  Front Microbiol       Date:  2022-05-25       Impact factor: 6.064

5.  Flucytosine-fluconazole cross-resistance in purine-cytosine permease-deficient Candida lusitaniae clinical isolates: indirect evidence of a fluconazole uptake transporter.

Authors:  Thierry Noël; Fabienne François; Patrick Paumard; Christiane Chastin; Daniel Brèthes; Jean Villard
Journal:  Antimicrob Agents Chemother       Date:  2003-04       Impact factor: 5.191

6.  In vitro evaluation of double and triple combinations of antifungal drugs against Aspergillus fumigatus and Aspergillus terreus.

Authors:  Eric Dannaoui; Olivier Lortholary; Françoise Dromer
Journal:  Antimicrob Agents Chemother       Date:  2004-03       Impact factor: 5.191

7.  Clinical efficacy and health implications of inconsistency in different production batches of antimycotic drugs in a developing country.

Authors:  Adenike A O Ogunshe; Adedayo A Adepoju; Modupe E Oladimeji
Journal:  J Pharm Bioallied Sci       Date:  2011-01
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.